allogeneic mesothelin TRuC

Allogeneic mesothelin TRuC is an investigational **off-the-shelf allogeneic T cell therapy** developed by **TCR2 Therapeutics** for **mesothelin-expressing solid tumors**. The product uses the company\u2019s **T cell Receptor fusion Construct** platform, in which donor-derived T cells are edited with **CRISPR/Cas9** to disrupt the endogenous T cell receptor and reduce alloreactivity and graft-versus-host risk, then transduced with a **mesothelin-directed TRuC transgene** incorporating the **MH1 single-domain antibody** fused to **TCR gamma and delta constant domains**. The intended mechanism is redirection of engineered T cells against **mesothelin-positive tumor cells**, with proposed applications including **mesothelioma, ovarian cancer, lung cancer, and pancreatic cancer**. Based on the provided context, this appears to have been a **preclinical research-stage program** for which TCR2 expected to identify a lead candidate in 2022.

Other names

allogeneic mesothelin TRuCallogeneic mesothelin TRuC-T cellsmesothelin-targeted allogeneic TRuC-T cells